Belsomra (suvorexant) was approved earlier this week by the FDA for use as needed to treat difficulty in falling and staying asleep. The drug blocks receptors for orexin – also known as hypocretin – the master hypothalamic regulator of the sleep-wake cycle. There are, in fact, two forms of orexin, A and B; hence it is a dual orexin …